GW Pharma details an impressive PhIII case for a cannabis-based drug for severe epilepsy as it preps an NDA
GW Pharmaceuticals lined up a straight shot at a key approval for Epidiolex today, publishing its impressive Phase III data for a severe form of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
